Home›Research›Compare›AOD-9604 vs Cagrilintide
Peptide ComparisonAOD-9604 vs Cagrilintide
AOD-9604
Advanced Obesity Drug 9604
Half-life: 30–60 minutes
197 providers listed
Cagrilintide
AM833
Half-life: ~7 days
21 providers listed
AOD-9604 and Cagrilintide target different goals — AOD-9604 for selective fat tissue lipolysis via GH C-terminal fragment mechanism, Cagrilintide for Metabolic. They're compared here for reference, not as direct substitutes.
AOD-9604
Half-life
30–60 minutes
Cagrilintide
Half-life
~7 days
AOD-9604 and Cagrilintide target different goals — AOD-9604 for GH / IGF Axis, Cagrilintide for Metabolic. They're compared here for reference; there isn't a single “better” choice between them.
AOD-9604
Cagrilintide
AOD-9604
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
About AOD-9604
AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AOD-9604
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
AOD-9604
Cagrilintide
Where to source these peptides
AOD-9604
197 listed
Browse directory →
Providers offeringCagrilintide
21 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AOD-9604 vs Cagrilintide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/aod-9604/cagrilintide